Department of Lymphoma/Myeloma, UT MD Anderson Cancer Center, Houston, TX, USA.
Curr Hematol Malig Rep. 2021 Feb;16(1):45-51. doi: 10.1007/s11899-021-00617-5. Epub 2021 Apr 2.
Follicular lymphoma is a common indolent non-Hodgkin lymphoma with survival improving in the modern era. Despite favorable responses and improving remission duration, FL remains largely incurable with patterns of relapsing and remitting disease with many patients requiring multiple lines of therapy. As our understanding of the malignant B-cell biology evolves, more targeted therapies have emerged for the treatment of follicular lymphoma.
Targeted therapies entering the treatment landscape of follicular lymphoma include lenalidomide in combination with rituximab based on the randomized AUGMENT. Tazemetostat, an EZH2 inhibitor, joins the list of targeted therapies approved based on single-arm phase 2 studies in the relapsed setting. There are three PI3K inhibitors currently approved and more under development. Herein, I will review the available evidence that supports the use of targeted therapy across the disease course of follicular lymphoma.
滤泡性淋巴瘤是一种常见的惰性非霍奇金淋巴瘤，在现代时代其生存率得到了提高。尽管有良好的反应和改善缓解持续时间，但 FL 仍然基本上无法治愈，疾病呈复发和缓解模式，许多患者需要多种治疗线。随着我们对恶性 B 细胞生物学的理解不断发展，针对滤泡性淋巴瘤的治疗出现了更多的靶向治疗。
进入滤泡性淋巴瘤治疗领域的靶向治疗包括来那度胺联合利妥昔单抗，这是基于随机 AUGMENT 试验的结果。EZH2 抑制剂他泽莫司汀也基于复发时的单臂 2 期研究被批准为靶向治疗药物之一。目前有三种 PI3K 抑制剂已获得批准，还有更多在开发中。在此，我将综述支持在滤泡性淋巴瘤病程中使用靶向治疗的现有证据。
